Issue 1/2007
Content (18 Articles)
Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer
N. Xu, P. Shen, X. C. Zhang, L. F. Yu, H. Y. Bao, G. M. Shi, S. Huang, J. Chen, H. B. Mou, W. J. Fang
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management
Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Hyun Jong Oh, Min Soo Kim, So Yeon Lee, Chang Wook Kim, U Im Chang, Soon Woo Nam, Sang Bok Cha, Young Joon Lee, Ho Jong Chun, Byung Gil Choi, Jae Young Byun, Seung Kew Yoon
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer
Keon Woo Park, Jin Seok Ahn, Young Suk Park, Jeeyun Lee, Jung Hoon Kang, Joon Oh Park, Ho Yeong Lim, Young-Hyuck Im, Won Ki Kang, Keunchil Park, Soon Il Lee
Thalidomide and celecoxib as potential modulators of irinotecan’s activity in cancer patients
Miguel Villalona-Calero, Larry Schaaf, Gary Phillips, Gregory Otterson, Kevin Panico, Wenrui Duan, Barbara Kleiber, Manisha Shah, Donn Young, Wan-Hong Wu, John Kuhn
Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study
Javier de Castro, Amalio Ordóñez, Dolores Isla, Alfredo Sánchez, Antonio Arrivi, José Luis Manzano, Manuel González Barón
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application
S. A. Veltkamp, C. Alderden-Los, A. Sharma, H. Rosing, J. H. Beijnen, J. H. M. Schellens
A phase I–II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens
Christos Kosmas, Nicolas Tsavaris, Konstantinos Syrigos, Angelos Koutras, George Tsakonas, Thomas Makatsoris, Nicolas Mylonakis, Athanasios Karabelis, George P. Stathopoulos, Haralambos P. Kalofonos
Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties
Veronika Jekerle, Werner Klinkhammer, Raymond M. Reilly, Micheline Piquette-Miller, Michael Wiese
Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis
C. K. L. P. Batista, J. M. S. C. Mota, M. L. P. Souza, B. T. A. Leitão, M. H. L. P. Souza, G. A. C. Brito, F. Q. Cunha, R. A. Ribeiro
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer
R. O’Connor, M. O’Leary, J. Ballot, C. D. Collins, P. Kinsella, D. E. Mager, R. D. Arnold, L. O’Driscoll, A. Larkin, S. Kennedy, D. Fennelly, M. Clynes, J. Crown
Fatality involving vinblastine overdose as a result of a complex medical error
Małgorzata Kłys, Tomasz Konopka, Mariusz Ścisłowski, Piotr Kowalski
Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients
Josephia R. Muindi, Yibing Peng, John W. Wilson, Candace S. Johnson, Robert A. Branch, Donald L. Trump
Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers
Maria L. N. Dias, Jesus P. Carvalho, Debora G. Rodrigues, Silvia R. Graziani, Raul C. Maranhão
Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha
Kotaro Miyake, Kunihiro Tsuchida, Hiromu Sugino, Satoru Imura, Yuji Morine, Masahiko Fujii, Mitsuo Shimada
RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide
Jan S. Moreb, Dagmara Muhoczy, Blanca Ostmark, James R. Zucali
RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide
Jan S. Moreb, Dagmara Mohuczy, Blanca Ostmark, James R. Zucali
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
Herbert I. Hurwitz, Roger B. Cohen, J. Patrick McGovren, Samit Hirawat, William P. Petros, Yutaka Natsumeda, Tomoko Yoshinari
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
Camillo Porta, Luciano Mutti, Gianfranco Tassi